A-FLUX Reducer System
Coronary Microvascular Dysfunction (CMD)
Early FeasibilityActive
Key Facts
Indication
Coronary Microvascular Dysfunction (CMD)
Phase
Early Feasibility
Status
Active
Company
About VahatiCor
VahatiCor is a clinical-stage medical device company targeting the significant unmet need in Coronary Microvascular Dysfunction (CMD), a condition affecting millions worldwide with debilitating chest pain. Its core innovation is the A-FLUX Reducer System, which utilizes proprietary SwiftCell® technology—a shape-memory, hourglass-shaped implant placed in the coronary sinus to immediately modulate blood flow and alleviate symptoms. The company recently secured an oversubscribed Series B financing to accelerate its early feasibility study (SERRA-I) and engineering development, positioning it to advance a novel interventional therapy in the cardiovascular space.
View full company profile